Aprea Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Aprea Therapeutics

21/03/2025 12:32

Aprea Therapeutics Inc APRE.OQ APRE.O is expected to show a rise in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

The Doylestown Pennsylvania-based  company is expected to report a 1,090.5% increase in revenue to $166.67 thousand from $14 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 69 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00​, above​ its last closing price of $2.42. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.68
-0.74
-0.64
Beat
14.1
Jun. 30 2024
-0.61
-0.63
-0.58
Beat
8.7
Mar. 31 2024
-0.79
-0.78
-0.67
Beat
13.7​
Dec. 31 2023
-0.77
-0.92
Missed
-19
​​Sep. 30 2023
-1.16
-1.16
-0.86
Beat
26.1
Jun. 30 2023
-1.42
-1.42
-0.87
Beat
38.9​
Mar. 31 2023
-1.52
-1.50
-1.34
Beat
11
Dec. 31 2022
-4.04
-3.08
-0.92
Beat
70.1

This summary was machine generated March 21 at 12:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)